ישראל - עברית - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - תמיסה לאינפוזיה - sodium lactate 0.32 %w/v; calcium chloride dihydrate 0.027 %w/v; potassium chloride 0.04 %w/v; sodium chloride 0.6 %w/v - calcium chloride - calcium chloride - source of water and electrolytes. regulation or maintenance of metabolic acidosis ( except lactic acidosis).

ישראל - עברית - Ministry of Health

remedix care ltd - glycine; l- alanine; l- aspartic acid; l- cysteine; l- glutamic acid; l- isoleucine; l- leucine; l- lysine; l- methionine; l- ornithine hydrochloride; l- phenylalanine; l- proline; l- serine; l- threonine; l- tryptophan; l- tyrosine; l- valine; l-arginine; l-histidine; taurine - תמיסה לאינפוזיה - l- valine 0.76 g / 100 ml; l- tyrosine 0.045 g / 100 ml; l- tryptophan 0.2 g / 100 ml; l- threonine 0.37 g / 100 ml; taurine 0.06 g / 100 ml; l- serine 0.4 g / 100 ml; l- proline 0.3 g / 100 ml; l- phenylalanine 0.42 g / 100 ml; l- ornithine hydrochloride 0.318 g / 100 ml; l- methionine 0.24 g / 100 ml; l- lysine 1.1 g / 100 ml; l- leucine 1.0 g / 100 ml; l- isoleucine 0.67 g / 100 ml; l-histidine 0.38 g / 100 ml; glycine 0.4 g / 100 ml; l- glutamic acid 1.0 g / 100 ml; l- cysteine 0.189 g / 100 ml; l- aspartic acid 0.6 g / 100 ml; l-arginine 0.84 g / 100 ml; l- alanine 0.8 g / 100 ml - lysine - lysine - primene 10 % is indicated in 1) children and infants 2) neonates at term or premature of normal or low birth weight when oral or enteral nutrition is impossible insufficient or contraindicated.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - gentamicin as sulfate 80 mg / 100 ml - solution for injection - gentamicin - treatment of serious infections caused by susceptible microorganisms.

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

ישראל - עברית - Ministry of Health

teva medical marketing ltd. - immunoglobulin normal human 50 mg/ml - powder for solution for injection - immunoglobulins, normal human, for intravascular adm. - replacement therapy in:• primary immunodeficiency syndromes (pid) such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia; - common variable immunodeficiency; - severe combined immunodeficiency; - wiskott aldrich syndrome.• myeloma or chronic lymphocytic leukaemia (cll) with severe secondary hypogammaglobulinaemia and recurrent infections.• children with congenital aids and recurrent infections.immunomodulation• idiopathic thrombocytopenic purpura (itp), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.• guillain barr? syndrome. in this case gammagard s/d (solvent/detergent) is only indicated in patients showing one of the following symptoms: - progressive paresis (the patient cannot walk more than 10 m on his own); - signs of a respiratory disorder (clinically observed or demonstrated by measuring the vital capacity at the patient’s bed); - signs of oropharyngeal paresis.• kawasaki disease.allogeneic bone marrow transplantation

ישראל - עברית - Ministry of Health

takeda israel ltd - immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 100 mg / 1 ml - immunoglobulins, normal human, for intravascular adm. - immunoglobulins, normal human, for intravascular adm. - ivig can be used in all age ranges, unless otherwise specified below.replacement therapy in:primary immunodeficiency syndromes with impaired antibody production.hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed.hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation.children and adolescents (age 0-18) with congenital aids and recurrent bacterial infections.hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (hsct).immunomodulationprimary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count.guillain barr? syndrome.kawasaki disease.

ישראל - עברית - Ministry of Health

megapharm ltd - cyclophosphamide - אבקה להכנת תמיסה לזריקה - cyclophosphamide 500 mg/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemi

ישראל - עברית - Ministry of Health

megapharm ltd - cyclophosphamide - אבקה להכנת תמיסה לזריקה - cyclophosphamide 1 g/vial - cyclophosphamide - cyclophosphamide - malignant diseases: cycophosphamide although effective alone in susceptible melignancies is more frequently used concurrently or sequentially with other antineoplastic drugs. the following malignancies are often susceptible. cycophosphamide treatment: 1) malignant lymphomas (stages iii and iv of the ann arbor staging system) hodgkin`s disease lymphocytic lymphoma (nodular or diffuse) mixed-cell type lymphoma histiocytic lymphoma burkitt`s lymphoma. 2) multiple myeloma. 3) leukemias: chronic lymphocytic leukemia chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis) acute myelogenous and monocytic leukemia acute lymphoblastic (stemcell) leukemia in children. 4) mycosis fungoides (advenced disease). 5) neuroblastoma (disseminated disease). 6) adenocarcinoma of the ovary. 7) retinoblastoma. 8) carcinoma of the breast. nonmallgnant disease biopsy proven "minimal change" nephrotic syndrome in children whose disease fails to respond adequately to another treatment. severe cases of systemi

ישראל - עברית - Ministry of Health

megapharm ltd - bleomycin sulfate - אבקה להכנת תמיסה לזריקה - bleomycin sulfate 15000 iu/vial - bleomycin - bleomycin - bleomycin is useful in the management of the following neoplasms: squamous cell carcinoma affecting the mouth, nasopharynx and paranasal sinuses, larynx, oesaphagus, cervix, vagina, penis and skin. well differentiated tumors usually respond better than anaplastic ones.hodgkin's disease and other malignant lymphomas, including mycosis fungoides. testicular carcinoma (seminoma and no seminoma) .malignant effusions of serous cavities (intrapleural and intraperitoneal).secondary indications in which bleomycin has been shown to be of some value include metastatic malignant melanoma, carcinoma of the thyroid lung and bladder. local treatment of refractory warts. bleomycin can be used as a single agent, but is generally used in combination with other cytotoxics and/or with radiation therapy.